Proactive Investors - Run By Investors For Investors

IXICO wins £9.1mln contract for Phase III clinical trial into Huntington’s disease

Giulio Cerroni, chief executive of IXICO Plc (LON:IXI), tells Proactive Investors they've inked a contract with a top 10 pharmaceutical company to provide imagining services for a Pivotal Phase III clinical trial into Huntington’s disease.

The contract, which is to be delivered over four years and carries a value of £9.1mln, extends the company's relationship with an existing client and is its fourth new contract relating to Huntington’s disease in the current financial year.

Meet MaxCyte, Primary Health Properties PLC, Scancell Holdings PLC and PCF Group Plc at our event, London , 25 April 2019. Register here »
View full IXI profile View Profile

IXICO PLC Timeline

December 11 2018

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use